VOLC announces plans to introduce new products at EuroPCR

Top Stories

»	India’s export outlook brighter as manufactured goods gain share: RBI
»	Private consumption driving growth in Q3 with rural India taking lead: RBI
»	Indian MSMEs create about 10 crore jobs in 15 months
»	Indian prefer Q-commerce for daily essentials, physical stores for high-value buying
»	Embedded finance to unlock $25 bn revenue opportunity for India’s platforms by 2030

PR Newswire | 24 May, 2010
SAN DIEGO: Volcano Corporation (Nasdaq: VOLC) announced today the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 â€“ 28 in Paris.

"Through both imaging and therapy, Volcano continues to lead the way in providing innovative solutions to best meet the complex needs of the interventional vascular physician and their patients," said Michel Lussier, Group President for Advanced Imaging Systems, Scientific Affairs, and Volcano Europe, Africa, and the Middle East (EAME). "We look forward to furthering the most progressive year of internally-developed technological innovations our company has seen yet that address the limitations of angiography. Not only do we continue to launch new-to-the-world technologies, we are also pleased to further optimize already commercialized intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products to make some of our best products even better."

Product Innovations

During EuroPCR, Volcano will showcase its new CE Mark approved additions to its suite of integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. The new product introductions from Volcano are:

    * Eagle EyeÂ® Platinum, an optimization of the #1 digital IVUS catheter, designed for improved deliverability with the convenience of radiopaque markers;
    * PrimeWire PRESTIGEâ„¢, the next generation FFR wire with enhanced torque response, vessel navigation and support for treating multi-vessel disease patients; and
    * The s5â„¢/s5iâ„¢ 3.2 software, which streamlines the workflow for both IVUS and FFR procedures and is compatible with more than 3,000 Volcano systems installed worldwide.

Volcano will also highlight its extensive pipeline of imaging and therapy products including the VIBEâ„¢ RX Vascular Imaging Balloon Catheter (which is awaiting CE Mark approval), Optical Coherence Tomography (OCT), and Forward Looking Imaging. All products will be available for demonstration at Booth #M07, Level 2. Volcano's IVUS and FFR technologies will also be highlighted in its partners' booths, including those of GE, Philips, and Siemens.

Volcano and Siemens will demonstrate continued development efforts to bring imaging co-registration to interventional cardiology. This technology will allow physicians to see their angiographic roadmap images linked side-by-side with the corresponding IVUS images in the cath lab. "Now, a patient's medical record will be even more complete," said Dave Sheehan, President of Volcano's IVUS and Physiology Businesses and Volcano Japan. "Plus, physicians will now have an additional layer of real-time precision to aid their strategic decision-making about how to best treat their patients." Volcano and Siemens plan to demonstrate the co-registration application from a live case in Erasmus University Medical Center in Rotterdam, the Netherlands.

Live Case Transmissions

Throughout EuroPCR, Volcano technology, including FFR, IVUS, and Image Co-Registration, will be featured in live case transmissions from around the world.

Clinical Trial Updates

Volcano's proprietary VHÂ® IVUS technology will be highlighted in two Late Breaking Data presentations (Times are Central European Time; events are at the Palais Des Congres De Paris):

VICTORY (VH In Carotids Observational Registry) is a European, multi-center prospective registry for carotid plaque characterization by VHÂ® IVUS during carotid stenting. Data on VICTORY will be presented at approximately 1:30 PM CET on Tuesday, May 25th, in Theatre Havane.

HEAVEN (Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration) is a Czech, prospective, randomized, multicenter controlled study that uses VHÂ® IVUS to measure the changes of plaque volume and the changes of plaque composition during atorvastatin and ezetimibe administration to the patient with stable angina. Data on HEAVEN will be presented at 8:48 AM CET on Thursday, May 27th, in Room Vendome.

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use digital and rotational IVUS imaging catheters, and advanced functionality options, such as VHÂ® IVUS tissue characterization and ChromaFloÂ®. Volcano also provides Physiology consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 5,200 Volcano IVUS and Physiology systems are installed worldwide, with approximately half of Volcano's revenues coming from outside the United States. Volcano's wholly-owned subsidiary, Axsun Technologies, develops and manufactures optical monitors, lasers and optical engines used in telecommunications, medical imaging, spectroscopy and other industrial applications. For more information, visit the company's website at www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the potential benefits of the products and procedures described above, further development and expansion, commercial release and market adoption of the company's technology, and the impact of clinical and other technical data. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly report on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.